CNN3 antibody targets calponin-3 (CNN3), a member of the calponin family of actin-binding proteins involved in cytoskeletal regulation. Calponin-3. encoded by the *CNN3* gene, is expressed in smooth muscle cells, fibroblasts, and certain non-muscle tissues, where it modulates cell contraction, motility, and mechanotransduction. Unlike its isoforms CNN1 and CNN2. CNN3 exhibits broader tissue distribution and dynamic roles in cellular processes such as differentiation, adhesion, and wound healing. It interacts with actin filaments, myosin, and other cytoskeletal components, influencing cell morphology and mechanical properties.
Antibodies against CNN3 are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate CNN3’s involvement in diseases such as cancer (e.g., tumor metastasis), cardiovascular disorders, and fibrotic conditions. Researchers also utilize CNN3 antibodies to explore its regulatory mechanisms in smooth muscle plasticity and tissue remodeling. Commercial CNN3 antibodies are typically raised in rabbits or mice, with specificity validated via knockout controls or siRNA silencing. Variations in antibody performance may arise due to post-translational modifications or tissue-specific isoforms, necessitating careful validation for experimental accuracy.